ClinicalTrials.gg
RecruitingNCT07469098Updated Mar 13, 2026

Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events

A Phase 2 interventional study of MDMA HCl in PTSD, sponsored by Sheba Medical Center. Recruiting at 2 sites in Israel. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Sheba Medical Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Stress Disorders, Post-Traumatic by Sheba Medical Center — 1 open to participants now, 1 under way, none of them phase 3. Stress Disorders, Post-Traumatic · Sheba Medical Center.

Started
2025
the only one that year
Phase 2
Only one
of the 16
Registered
16th of 16
by date

Among the 16 studies in Stress Disorders, Post-Traumatic by Sheba Medical Center, this one is the only one that started in 2025, is the only one in phase 2, and was the 16th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

1 of the 16 studies in Stress Disorders, Post-Traumatic by Sheba Medical Center is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Stress Disorders, Post-Traumatic by Sheba Medical Center, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability and effectiveness of group-based MDMA-assisted therapy compared to individual MDMA-assisted therapy in participants with PTSD, who were diagnosed following the events of 7 October 2023. The main questions it aims to answer are: safety and tolerability? effectiveness? Researchers will compare group-based MDMA-assisted therapy to individual MDMA-assisted therapy to see if group-based MDMA-assisted therapy is not inferior to individual MDMA-assisted therapy, in terms of safety and effectiveness.

Participants will be randomized to one of two study arms: group-based MDMA-assisted therapy or individual MDMA-assisted therapy receive MDMA HCl administered orally in a divided dose. Participate in preparatory sessions, MDMA dosing sessions, and integration sessions. Be monitored for adverse events and suicidality (C-SSRS). Be monitored by an external Data Safety Monitoring Board (DSMB).

Read the detailed description

PTSD (post-traumatic stress disorder) is a severe and debilitating disorder that may occur following a traumatic event, with significant consequences on daily life, such as inability to form beneficial relationships, inability to maintain employment, reduced cognitive and psycho-social functioning, depression, anxiety and alcohol disorders and use of addictive substances. Available PTSD treatments include medications and therapy, but they effectively treat only a small portion of people, indicating a need to develop treatments targeting durable remission of PTSD.

MDMA is a phenylisopropylamine derivative. MDMA increases levels of serotonin and also increases levels of oxytocin and vasopressin, which are associated with increased trust and reduced reactivity to threatening situations. MDMA is not used as a treatment by itself, but as an adjunct that enhances the effectiveness of psychotherapy.

Participants will complete pre-screening. Screening and enrollment procedures include review of medical and psychiatric history, documentation of prior/current medications, and completion of questionnaires. Participants will be asked to complete questionnaires throughout the study, including during screening and at multiple time points across study visits, to assess symptoms and other study-related measures. Eligible participants will be randomized, with allocation managed centrally, to one of two treatment arms.

Prior to administration of the investigational product, participants will attend preparatory sessions. MDMA HCl will be administered orally in a divided dose, with a supplemental dose administered 1.5 to 2 hours after the initial dose. During dosing sessions, participants will be monitored, including measurement of vital signs by trained medical staff. Safety procedures include physical examination, urine drug testing, ECG assessment, and safety laboratory tests as specified in the protocol.

Safety monitoring will include assessment of adverse events and C-SSRS. Study safety will be overseen by an external Data Safety Monitoring Board (DSMB).

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are at least 18 years old.
  2. At Screening, meet criteria for current PTSD that has been diagnosed past 7/10/23 and the events following.
  3. At Screening, have at least moderate PTSD symptoms in the last month, based on PCL-5 total score of 36 or greater, conducted by certified Study coordinators.
  4. Are fluent in speaking and reading the predominantly used or recognized language of the study site (Hebrew).
  5. Are able to swallow pills.
  6. Participant where in psychotherapy prior to the study. If the participant is still in psychotherapy during study enrollment, they consent to continue therapy during the study and provide consent for the investigator to communicate with the therapist as needed.
  7. Must provide a contact (relative, spouse, close friend, or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable.
  8. Must agree to inform the investigators within 48 hours of any medical conditions and procedures.
  9. Agree to the following lifestyle modifications (see lifestyle modifications section) : comply with requirements for fasting and refraining from certain medications prior to Experimental Sessions, not participate in any other interventional clinical trials during the duration of the study, remain overnight at the study site after each Experimental Session and be driven home after, and commit to medication dosing, therapy, and study procedures.
  10. If able to become pregnant (i.e. assigned female at birth, fertile, following menarche and until becoming unless permanently sterile), must have a highly sensitive negative pregnancy test at study entry and prior to each Experimental Session, and must agree to use adequate through 10 days after the last Experimental Session. Adequate birth control methods include intrauterine device (IUD), injected, implanted, intravaginal, or transdermal hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner, or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones (i.e. condom plus diaphragm, condom or diaphragm plus spermicide, oral hormonal contraceptives plus spermicide or condom).
  11. Holds a permanent address in the next 6 months.

Medical History

  1. May have well-controlled hypertension that has been successfully treated with anti-hypertensive medicines, if they pass additional screening to rule out underlying cardiovascular disease.
  2. May have asymptomatic virus (HCV) that has previously undergone evaluation and treatment as needed.
  3. May have alcohol or substance use disorder if the participant is not in withdrawal or requiring detox. Participants must have a plan, agreed upon by the investigator, therapy team, and study physician, to reduce use of alcohol or other substances and to manage symptoms without self-medicating. Enrollment will require that, in the judgment of the investigator, therapy team, and study physician, the plan for decreasing substance use is realistic and has a good chance of succeeding in order to prevent substance use from impacting the safety or efficacy of the treatment.
  4. May have a history of or current Diabetes Mellitus (Type 2) if additional screening measures rule out underlying cardiovascular disease, if the condition is judged to be stable on effective management, and with approval by the study physician.
  5. May have hypothyroidism if taking adequate and stable thyroid replacement medication.
  6. May have a history of, or current, glaucoma if approval for study participation is received from an ophthalmologist.

Exclusion criteria

Exclusion Criteria:

  1. Are not able to give adequate .
  2. Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or study clinician, contraindicates participation in the study.
  3. Active military duty expected in the following 12 months.
  4. Death of a close person in the past 6 months.

Psychiatric History

  1. Have received Electroconvulsive Therapy, Transcranial Magnetic Stimulation, or Ketamine Therapy within 12 weeks of enrollment.
  2. Have a history of, or a current diagnosis of schizophrenia, schizoaffective disorder, major depressive disorder with psychotic features, psychotic disorder, bipolar disorder I or II (with or without psychotic features), or dissociative identity disorder assessed by medical history, investigator interview and the Mini-International Neuropsychiatric Interview (MINI).
  3. Have a current substance use disorder other than caffeine or nicotine that the investigators, therapy team, and/or study physician judge to be a safety concern for enrollment in the study or that could interfere with the therapeutic process or with other aspects of study participation as assessed by clinical interview per as well as Audit and Dudit questionnaires. Any participant who is not able to agree or adhere to a plan to reduce use and manage symptoms will not be enrolled.
  4. Have an active illicit (other than cannabis) or prescription drug substance use disorder at any severity within 12 months prior to enrollment.
  5. Have current Personality Disorders Cluster A (paranoid, schizoid, schizotypal), Cluster B (antisocial, borderline, histrionic, narcissistic), or Cluster C (avoidant, dependent, obsessive-compulsive) assessed via SCID-5-PD.
  6. Any participant presenting current serious suicide risk, as determined through psychiatric interview, responses to C-SSRS, and clinical judgment of the investigator will be excluded; however, history of suicide attempts is not an exclusion. Any participant who is likely to require hospitalization related to suicidal ideation and behavior, in the judgment of the investigator, will not be enrolled. Any participant presenting with the following on the Baseline C-SSRS will be excluded:

    1. Suicidal ideation score of 4 or greater within the last 6 months of the assessment at a frequency of once a week or more.
    2. Suicidal ideation score of 5 within the last 6 months of the assessment.
    3. Any suicidal behavior, including suicide attempts or preparatory acts, within the last 6 months of the assessment. Participants with non-suicidal self-injurious behavior may be included if approved by the study physician.
  7. Would present a serious risk to others as established through clinical interview and contact with treating psychiatrist.
  8. Have a blood or needle phobia that interferes with obtaining necessary blood work.
  9. Have an immediate family member diagnosed with a psychotic disorder to the participant's knowledge.

Medical History

  1. Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate. This includes, but is not limited to, a history of myocardial infarction, cerebrovascular accident, or aneurysm. Participants with other mild, stable chronic medical problems may be enrolled if the study physician and sponsor-investigator agree the condition would not significantly increase the risk of MDMA administration or be likely to produce significant symptoms during the study that could interfere with study participation or be confused with side effects of the use of MDMA. Examples of stable medical conditions that could be allowed include, but are not limited to Diabetes Mellitus (Type 2), (HIV) infection, Gastroesophageal Reflux Disease (GERD), etc. Any medical disorder judged by the investigator to significantly increase the risk of MDMA administration by any mechanism would require exclusion.
  2. Have uncontrolled essential hypertension using the standard criteria of the American Heart Association (values of 140/90 milligrams of Mercury [mmHg] or higher assessed on three separate occasions).
  3. Have a history of ventricular arrhythmia at any time, other than premature ventricular contractions (PVCs) in the absence of ischemic heart disease.
  4. Have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation.
  5. Have a history of arrhythmia, other than premature atrial contractions (PACs) or occasional PVCs in the absence of ischemic heart disease, within 12 months of screening. Participants with a history of atrial fibrillation, atrial tachycardia, atrial flutter or paroxysmal supraventricular tachycardia or any other arrhythmia associated with a bypass tract may be enrolled only if they have been successfully treated with ablation and have not had recurrent arrhythmia for at least one year off all antiarrhythmic drugs and confirmed by a cardiologist.
  6. Have a marked Baseline prolongation of /QTc interval e.g., repeated demonstration of a QTc interval > 450 milliseconds (ms) in males and >460 ms in females corrected using Fridericia's formula. For transgender or non-binary participants, QTc interval will be evaluated based on sex assigned at birth, unless the participant has been on hormonal treatment for 5 or more years.
  7. Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
  8. Require use of concomitant medications that prolong the QT/QTc interval during Experimental Sessions. Refer to protocol section on Concomitant Medications.
  9. Have symptomatic liver disease or have significant liver enzyme elevations.
  10. Have history of hyponatremia or hyperthermia.
  11. Weigh less than 48 kilograms (kg).
  12. Have engaged in ketamine-assisted therapy or used ketamine within 12 weeks of enrollment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
168 participants (estimated)

Study arms

  • Experimental
    Group-based MDMA-assisted therapy

    Participants will receive group-based MDMA-assisted therapy (up to 7 participants per group). Each group will include participants with the same type of trauma. MDMA HCl will be administered orally during dosing sessions in a divided dose, with a supplemental dose administered 1.5 to 2 hours after the initial dose. Participants will attend preparatory sessions and integration sessions according to the protocol.

    Drug: MDMA HCl

  • Experimental
    Individual MDMA-assisted therapy

    Participants will receive individual MDMA-assisted therapy. MDMA HCl will be administered orally during dosing sessions in a divided dose, with a supplemental dose administered 1.5 to 2 hours after the initial dose. Participants will attend preparatory sessions and integration sessions according to the protocol.

    Drug: MDMA HCl

Interventions

  • DrugMDMA HCl

    MDMA HCl will be administered orally during dosing sessions in a divided dose. In the first dosing session, participants will receive 80 mg MDMA HCl with a supplemental dose of 40 mg administered 1.5 to 2 hours after the initial dose. In the second and third dosing sessions, participants will receive 120 mg MDMA HCl with a supplemental dose of 60 mg administered 1.5 to 2 hours after the initial dose.

06

What researchers measure

Primary outcomes

  1. Change in PTSD symptoms as measured by CAPS-5

    Change from baseline in PTSD symptoms as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).

    Time frame: Baseline to end-of-treatment visit (Week 17 in the GMAT; Week 13 in the IMAT)

  2. Change in PTSD symptoms as measured by PCL-5

    Change from baseline in PTSD symptoms as measured by the PTSD Checklist for DSM-5 (PCL-5).

    Time frame: Baseline to end-of-treatment visit (Week 17 in the GMAT; Week 13 in the IMAT)

Secondary outcomes

  1. Safety and tolerability

    Severity, incidence and frequency of adverse events (AEs), treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs) and serious adverse events (SAEs).

    Time frame: From baseline through end-of-study visit (Week 17 in the GMAT; Week 13 in the IMAT)

  2. Suicidal ideation and behavior assessed with C-SSRS

    Incidence of serious suicidal ideation and positive suicidal behavior assessed with the Columbia Suicide Severity Rating Scale (C-SSRS).

    Time frame: From baseline through end-of-study visit Week 17 in the GMAT; Week 13 in the IMAT), assessed throughout the treatment period

  3. Change in systolic and diastolic blood pressure

    Mean change in systolic and diastolic blood pressure from pre-investigational product (IP) administration to the end of each Experimental Session.

    Time frame: From pre-IP administration to end of each Experimental Session (Weeks 6, 10, and 14 in the GMAT arm; Weeks 4, 7, and 10 in the IMAT arm)

  4. Change in heart rate

    Mean change in heart rate from pre-investigational product (IP) administration to the end of each Experimental Session.

    Time frame: From pre-IP administration to end of each Experimental Session (Weeks 6, 10, and 14 in the GMAT arm; Weeks 4, 7, and 10 in the IMAT arm)

  5. Change in respiratory rate

    Mean change in respiratory rate from pre-investigational product (IP) administration to the end of each Experimental Session.

    Time frame: From pre-IP administration to end of each Experimental Session (Weeks 6, 10, and 14 in the GMAT arm; Weeks 4, 7, and 10 in the IMAT arm)

  6. Change in body temperature

    Mean change in body temperature from pre-investigational product (IP) administration to the end of each Experimental Session.

    Time frame: From pre-IP administration to end of each Experimental Session (Weeks 6, 10, and 14 in the GMAT arm; Weeks 4, 7, and 10 in the IMAT arm)

07

Study locations

2 of 2 sites recruiting
  • Mental Health Medical Center Beer Sheva
    Beersheba, Israel
    Recruiting
    • Oded Arbel · Contact
  • Lev-Hasharon Mental Health Medical Center
    Pardesiyya, Israel
    Recruiting
    • Kfir Feffer · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.

Of 87 non-industry phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 59. This study's planned 36 months is below that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Mar 13, 2026
StartActual
Dec 24, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Mar 31, 2029
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07469098
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Dec 24, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Mar 13, 2026

Study contacts

Revital Amiaz
Contact
revital.amiaz@sheba.health.gov.il
972542378757
Revital Amiaz
principal investigator · Sheba Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion